Aleo-emodin for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Aleo-emodin may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed aleo-emodin in detail.
, Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID‐19 and facial neuritis, World Journal of Otorhinolaryngology - Head and Neck Surgery, doi:10.1002/wjo2.185
AbstractObjectiveCoronavirus disease‐2019 (COVID‐19) can cause not only respiratory symptoms but also facial paralysis. Lianhua Qingwen (LHQW) has been reported to have therapeutic effects on COVID‐19 and facial neuritis (FN). We explored the potential mechanism of LHQW in the treatment of COVID‐19 and FN through a network‐pharmacology approach.MethodsActive compounds and relevant targets of LHQW were obtained from the databases of Traditional Chinese Medicine Systems Pharmacology Database, HERB, UniProt Knowledge Base, SwissADME, and Swiss Target Prediction. Disease targets of COVID‐19 and FN were acquired from Gene Cards. Database For Annotation, Visualization And Integrated Discovery and Metascape were used to search the biological functions of intersecting targets. After identifying the core targets and their corresponding ingredients, KEGG Mapper analyzes the localization of core targets in key pathways. AutoDock were employed to conduct molecular docking of the core targets and their corresponding ingredients.ResultsWe obtained four core genes: interleukin (IL)‐8, IL‐1B, IL‐6, and tumor necrosis factor (TNF)‐α. Database searching revealed the anti‐inflammatory and antiviral effects of LHQW may be related to the action of aleo‐emodin, hyperforin, kaempferol, luteolin, and quercetin on these four genes by regulating the pathways of IL‐17 and NOD‐like receptor. The molecular‐docking results of the four core targets and their corresponding active ingredients showed good binding activity between receptors and ligands.ConclusionsWe uncovered the active ingredients, potential targets, and biological pathways of LHQW for COVID‐19 and FN coinfection. Our data provide a theoretical basis for further exploration of the mechanism of action of LHQW in treatment of COVID‐19 and FN.